Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Breast Cancer
77%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
66%
Community Setting
66%
Acquired Resistance
66%
Dermatomyositis
66%
Cefotetan
66%
Mastectomy
66%
Maintenance Rituximab
66%
Targeted Therapy
66%
Small Cell Lung Cancer
66%
R-CHOP Chemotherapy
66%
Non-small Cell Lung Cancer (NSCLC)
66%
Rituximab Maintenance
66%
Surgical Treatment of Breast Cancer
66%
Primary Resistance
66%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
66%
Chemotherapy
66%
Progression-free Survival
66%
Well Tolerated
66%
Low-grade Lymphoma
66%
Cardiac Magnetic Resonance Imaging (cMRI)
66%
Previously Untreated Patients
66%
Factor VIII Inhibitor
66%
Retrospective Analysis
66%
Medical Treatment
66%
Physical Therapists
66%
Lymphedema
58%
Mammogram
44%
FVIII Inhibitors
44%
Bleeding Episodes
44%
Erythematous Rash
44%
Exon 20
33%
Targeted Agents
27%
Physical Therapy
25%
Cancer-related Fatigue
25%
Factor VIII (FVIII)
22%
Right Lung
22%
Thoracic Region
22%
Inflammatory Skin
22%
External Beam Radiation
22%
Rituximab
22%
Consolidation Chemotherapy
22%
Drug Administration
22%
Novel Agents
22%
Older Men
22%
Hematuria
22%
Thorax
22%
Venipuncture
22%
4-cycle
22%
Supportive Care
22%
Medicine and Dentistry
Rituximab
88%
Epidermal Growth Factor Receptor
66%
Targeted Therapy
66%
Small Cell Lung Cancer
66%
Non Small Cell Lung Cancer
66%
Blood Clotting Factor 8 Inhibitor
66%
Dermatomyositis
66%
Epidermal Growth Factor Receptor Kinase Inhibitor
66%
Chemotherapy
66%
Non-Hodgkin Lymphoma
66%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
33%
Exon
33%
Progression Free Survival
33%
Maintenance Therapy
33%
Lung Cancer
26%
Biological Marker
26%
Hematuria
22%
Infection
22%
Vein Puncture
22%
Autoimmune Disease
22%
Substitution Therapy
22%
Adenosine Triphosphate
16%
Adenocarcinoma
16%
Histology
16%
Combination Chemotherapy
13%
Cancer Mortality
13%
Clinical Trial
13%
Radiation Therapy
13%
Tumor Cell
13%
Malignant Neoplasm
13%
Treatment of Small Cell Lung Cancer
13%
Effective Treatment
13%
Signal Transduction
13%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy Regimens
100%
Dermatitis
66%
Rituximab
66%
Small Cell Lung Cancer
66%
Nonhodgkin Lymphoma
66%
Cefotetan
66%
Erythema
44%
Progression Free Survival
33%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
33%
Skin Manifestation
22%
Carboplatin
22%
Ionizing Radiation
22%
Docetaxel
22%
Squamous Cell Carcinoma
22%
Drug Administration
22%
Acute Cholecystitis
22%
Biological Marker
22%
Lung Cancer
22%
Clinical Trial
11%
Cancer Mortality
11%
Neoplasm
11%
Malignant Neoplasm
11%